The eligible studies included four articles for ER‐positive and HER2‐negative breast cancer, one article for metastatic or advanced breast cancer, one article for metastatic germ cell tumor, one article for advanced or metastatic liposarcoma, and two articles for other Rb‐positive tumors. This evidence concerns the gene ERBB2 and breast cancer.